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Abstract   
Background: Currently diabetes mellitus is one of the largest global health emergencies. As the 
morbidity and mortality rate of diabetes is increasing worldwide, it is necessary to investigate 
medicinal plants for new antidiabetic drugs that can lead to effective and safe pharmacotherapy. 
Objective: To evaluate the antidiabetic and antidyslipidemic activities of 80% methanolic leaf 
and seed extracts of Calpurnia aurea (Ait.) Benth. (Fabaceae) in mice. 
Method: Blood glucose lowering activity of the three doses (100mg/kg, 200mg/kg and 400 
mg/kg) of hydromethanolic leaf extract and three doses (2.75 mg/kg, 5.5 mg/kg and 11 mg/kg) of 
the hydromethanolic seed extract of Calpurnia aurea was studied in four animal models; 
normoglycemic mice, oral glucose loaded mice, single dose treated diabetic mice and repeated 
dose treated diabetic mice. Additionally, the effect of the extracts on body weight and serum 
lipid profile was studied in the repeated dose treated diabetic mice. Glibenclamide (5 mg/kg) was 
used as a standard drug in all animal models. Blood glucose level was measured using a glucose 
meter; whereas serum lipid levels were measured using an automated chemistry analyzer. Data 
were analyzed using one way analysis of variance followed by Tuckey’s post hoc test. 
Result: Hydromethanolic extract of calpurnia aurea seeds showed blood glucose lowering 
activity in all animal models, and it improves body weight loss and diabetic dyslipidemia in 
diabetic animals. But, hydromethanolic extract of Calpurnia aurea leaves lack significant blood 
glucose lowering activity in all animal models, and it didn’t significantly improve the body 
weight loss and diabetic dyslipidemia of diabetic mice after 14 days of treatment. 
Conclusion: This study revealed that hydromethanolic extract of Calpurnia aurea seeds has a 
significant antidiabetic and antidyslipidemic activity justifying the traditional use of the plant for 
diabetes mellitus. But, it was found that the leaves of the plant lack significant antidiabetic and 
antidyslipidemic activities.  
Key words: Diabetes mellitus, Calpurnia aurea, Streptozotocin, Mice 
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1 Introduction 
1.1 Diabetes mellitus  
Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia with 
disturbances of carbohydrate, fat and protein metabolism resulting from abnormalities in insulin 
secretion, insulin action, or both (1). It is one of four priority non-communicable public health 
problems targeted for action by world leaders (2). The chronic hyperglycemia of diabetes is 
associated with long-term microvascular complications affecting the eyes, kidneys and nerves, as 
well as an increased risk for cardiovascular disease (1, 3). Prediabetes is a term referring to 
impaired fasting glucose, impaired glucose tolerance or a glycated hemoglobin (HbA1C) of 6.0% 
to 6.4%, each of which places individuals at high risk of developing diabetes and its 
complications (1).  
1.1.1 Prevalence and global burden of diabetes mellitus  
Globally, 422 million adults were living with diabetes in 2014. Over the past decade, diabetes 
prevalence has risen faster in developing countries than in developed countries (2). The global 
prevalence of DM is expected to rise to 552 million by 2030 (4) and 642 million by 2040 (5). 
The most important demographic change to diabetes prevalence across the world appears to be 
the increase in the proportion of people greater than 65 years of age (6). 
Diabetes and its complications are major causes of early death in most countries. Approximately 
5 million people aged between 20 and 79 years died from diabetes in 2015, equivalent to one 
death every six seconds. Additionally, DM accounted for 14.5% of global all-cause mortality 
among people in this age group (5). 
Globally, 12% of the total health expenditure was spent on diabetes in 2015 (5). The global 
health expenditure on diabetes is estimated to be at least USD 376 billion in 2010 and it is 
expected to rise to USD 490 billion in 2030 (7) and USD 802 billion in 2040 (5).  
In 2015, 14.2 million adults aged 20-79 have diabetes in Africa, representing a regional 
prevalence of 2.1 - 6.7%. Africa’s most populous countries have the highest numbers of people 
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with diabetes, South Africa (2.3 million), Democratic Republic of Congo (1.8 million), Nigeria 
(1.6 million) and Ethiopia (1.3 million) (5).  
1.1.2 Classification and pathophysiology of diabetes mellitus  
There are three main types of diabetes; type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus 
(T2DM), and gestational diabetes mellitus (GDM). Other less common types of diabetes are 
monogenic diabetes and secondary diabetes (5, 8).  
1.1.2.1 Type 1 diabetes mellitus 
Type 1 DM accounts for 5% to 10% of all DM cases. It is an autoimmune disease involving 
destruction of the insulin secreting β-cells of the pancreas which takes place over many years. 
Markers of the immune destruction of the beta-cell include islet cell autoantibodies, 
autoantibodies to insulin, autoantibodies to glutamic acid decarboxylase (GAD), and 
autoantibodies to the tyrosine phosphatases IA-2 and IA-2b. One and usually more of these 
autoantibodies are present in 85-90% of individuals when fasting hyperglycemia is initially 
detected (8). Autoimmune destruction of β-cells has multiple genetic predispositions and is also 
related to environmental factors that are still poorly defined (9). Type 1 DM commonly occurs in 
childhood and adolescence, but it can occur at any age, even in the 8
th
 and 9
th
 decades of life and 
it often develops suddenly (5).  
1.1.2.2 Type 2 diabetes mellitus 
Type 2 DM accounts for 90-95% of all diabetes cases (8). The pathophysiology of type 2 
diabetes mellitus is characterized by peripheral insulin resistance and declining β-cell function, 
and both are influenced by genetic and environmental factors (10).  
The primarily factor for insulin resistance in type 2 diabetes is post binding defects in insulin 
action, including reduced insulin receptor tyrosine kinase activity, insulin signal transduction 
abnormalities, decreased glucose transport, diminished glucose phosphorylation, and impaired 
glycogen synthase activity. Diminished insulin binding, when present, is modest and secondary 
to down-regulation of the insulin receptor by chronic hyperinsulinemia (11).  In T2DM, the 
sensitivity of the beta-cell to glucose is impaired, and there is also a loss of responsiveness to 
other stimuli such as insulinotropic gastrointestinal hormones and neural signaling. This defect is 
compounded by a gradual loss of beta-cell mass over time, potentially related to toxic effects of 
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hyperglycemia (12). Chronic hyperglycemia causes toxic effects on structure and function of 
organs, including the pancreatic islet through multiple biochemical pathways which leads to the 
formation of reactive oxygen species that, in excess and over time, cause chronic oxidative 
stress, which in turn causes defective insulin gene expression and insulin secretion as well as 
increased apoptosis of beta cells (figure 1) (13, 14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Six biochemical pathways along which glucose metabolism can form reactive oxygen 
species. DAG, diacylglycerol 
1.1.2.3 Gestational diabetes 
Gestational DM is defined as carbohydrate intolerance resulting in hyperglycemia of variable 
severity with onset or first recognition during pregnancy. The disorder affects 5% to 7% of all 
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pregnancies and its frequency is rising worldwide (15). Patients with GDM have a 30% to 50% 
chance of developing DM, usually type 2 DM (16).  
Insulin resistance increases in normal pregnancy due to progressively rising levels of feto-
placental hormones such as progesterone, cortisol, growth hormone, prolactin and human 
placental lactogen (15). 
1.1.2.4 Other less common types of DM 
Other less common types of diabetes include monogenic diabetes and secondary diabetes. 
Monogenic diabetes is the result of a genetic mutation. Examples of monogenic diabetes include 
Maturity-Onset Diabetes of the Young (MODY) and Neonatal Diabetes Mellitus. Secondary 
diabetes arises as a complication of other diseases, such as hormone disturbances (Cushing’s 
disease or acromegaly) or diseases of the pancreas (5, 8).  
Maturity-Onset Diabetes of the Young can result from mutations in at least six different genes, 
which were numbered according to the sequence of discovery. One of these encodes the 
glycolytic enzyme, glucokinase (MODY2), which is an important glucose sensor, whereas the 
others encode transcription factors: hepatocyte nuclear factor (HNF) 4α (MODY1), HNF-1α 
(MODY3), insulin promoter factor-1 (IPF1/Pdx-1; MODY4), HNF-1β (MODY5) and 
neurogenic differentiation factor 1 (NeuroD1; MODY6) (17, 18).  
1.1.3 Risk factors for diabetes 
The exact causes of type 1 diabetes are unknown. It is the result of a complex interaction 
between genes and environmental factors; though no specific environmental risk factors have 
been shown to cause a significant number of cases. The risk of type 2 diabetes is determined by 
interplay of genetic and metabolic factors. Overweight and obesity are the strongest risk factors 
for type 2 diabetes. Risk factors for GDM include age (the older a woman of reproductive age is, 
the higher her risk of GDM); overweight or obesity; excessive weight gain during pregnancy; a 
family history of diabetes; GDM during a previous pregnancy (2, 5).  
1.1.4 Diabetes mellitus and dyslipidemia 
Diabetes mellitus directly affect lipid levels (19). Diabetic patients tend to have higher serum 
levels of triglyceride (TG), lower high-density lipoprotein cholesterol (HDL-C), and similar 
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serum values for low-density lipoprotein cholesterol (LDL-C) but with high small dense LDL 
levels when compared with non-diabetic patients (20, 21). Hypertriglyceridemia is considered 
the dominant lipid abnormality and plays a pivotal role in determining the characteristic lipid 
profile of diabetic dyslipidemia (21). Insulin deficiency in diabetes reduces suppression of 
hormone sensitive lipase activity thereby increasing intracellular hydrolysis of TGs in the 
adipose tissue, consequently releasing free fatty acids (FFA) in the portal circulation. These FFA 
stimulate the assembly and secretion of very-low-density lipoprotein (VLDL) from the liver, 
resulting in excess circulating TG concentration (20, 21). Insulin deficiency and resistance is also 
associated with decreased lipolytic activity of lipoprotein lipase (LPL) which leads to decreased 
clearance of very low density lipoproteins (VLDLs) and chylomicrons (22).  
1.1.5 Diagnosis of Diabetes Mellitus 
Criteria for the diagnosis of diabetes includes; when HbA1C > 6.5% (the test should be performed 
in a laboratory using a method that is National Glycohemoglobin Standardization Program 
certified and standardized to the Diabetes Control and Complications Trial assay), or fasting 
blood glucose ≥126 mg/dl (fasting is defined as no caloric intake for at least 8 h), or in a patient 
with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose > 
200 mg/dl (8).  
Screening for GDM is done with a standard oral glucose tolerance test (OGTT). The 75 g OGTT 
is done in the morning after an overnight fast of at least 8 hours with plasma glucose 
measurements of fasting and at 1 and 2 hours following the oral glucose load. The diagnosis is 
confirmed when any of the following plasma glucose values are obtained: Fasting > 92 mg/dl 
(5.1 mmol/L), 1 h > 180 mg/dl (10.0 mmol/l) or 2 h > 153 mg/dl (8.5 mmol/l) (8, 23, 24). 
1.1.6 Treatment of diabetes mellitus 
The primary goals of DM management are to reduce the risk for microvascular and 
macrovascular disease complications, to ameliorate symptoms, to reduce mortality, and to 
improve quality of life (24).  
Insulin replacement therapy is the mainstay for patients with type 1 DM while diet, lifestyle 
modifications and oral hypoglycemic agents are considered the cornerstone for the management 
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of type 2 DM. Insulin is also important in type 2 DM when blood glucose levels cannot be 
controlled by diet, weight loss, exercise and oral medications (16). Oral hypoglycaemic agents 
include α-glucosidase inhibitors, biguanides, Insulin secretagogue (meglitinides and 
sulfonylureas), peroxisome proliferator-activated receptor γ agonists (thiazolidinediones or 
glitazones), Dipeptidyl peptidase-4 (DPP-4) inhibitors, dopamine agonists, bile acid sequestrants, 
and sodium-glucose cotransporter 2 inhibitors (25). The oral hypoglycemic agent metformin 
should be included in the therapy for all type 2 DM patients, if tolerated and not contraindicated, 
as it is the only oral antihyperglycemic medication proven to reduce the risk of total mortality, 
according to the United Kingdom Prospective Diabetes Study (26).  
 
Figure 2: Major target organs and mechanism of action of oral hypoglycemic agents in type 2 
diabetes mellitus. TZD = thiazolidinedione; FFA = free fatty acid; AGI = α-glucosidase inhibitor 
(27).  
Dietary restrictions remain the mainstay of GDM management, and suitable physical exercise 
can help too. Rapid-acting insulin analogues (lispro and aspart) are novel treatments for 
improving metabolic control by reducing postprandial glycemia, while long-acting insulin 
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analogues need further study on the related safety issues before they can be prescribed. 
Numerous studies have found glyburide and metformin safe in GDM pregnancies, but more 
randomized controlled trials are needed in type 2 diabetic and GDM women, with a long-term 
follow-up of mother and child, to confirm these results (15, 25).  
 
Figure 3: Management of gestational diabetes. FPG, fasting plasma glucose; 2 h PPG, 2 hour 
postprandial glucose; MPG, mean plasma glucose (15).  
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
 
1.2 Medicinal plants and diabetes mellitus 
Medicinal plants have been used in traditional health care systems since prehistoric times and are 
still the most important health care source for the vast majority of the population around the 
world (28). It is estimated that 70-80% of people worldwide rely on traditional herbal medicine 
to meet their primary health care needs. Globally, millions of people rely on medicinal plants not 
only for primary health care, but also for income generation and livelihood improvement (29).  
Traditional herbal medicines play an important role in the management of diabetes mellitus. It 
was estimated that more than 1000 plant species are being used as folk medicine for diabetes 
(28). In recent years, herbal medicines have started to gain importance as a source of 
hypoglycemic agents. The families of plants with the most potent hypoglycemic effects include 
Leguminoseae (Fabaceae), Lamiaceae, Liliaceae, Cucurbitaceae, Asteraceae, Moraceae, 
Rosaceae, Euphorbaceae and Araliaceae (30). Biological actions of the plant products used as 
alternative medicines to treat diabetes are related to their chemical composition. Herbal products 
or plant products which are rich in phenolic compounds, flavonoids, terpenoids, alkaloids, and 
other constituents have shown blood glucose lowering activity (28, 30-32). Particularly, 
schulzeines A, B, and C, radicamines A and B, 2,5-imino-1,2,5-trideoxy-L-glucitol, beta-
homofuconojirimycin, myrciacitrin IV, dehydrotrametenolic acid, corosolic acid, 4-(a 
rhamnopyranosyl) ellagic acid, and 1,2,3,4,6-pentagalloylglucose are among the isolated 
compounds from plants which have shown significant antidiabetic activities (32). 
The antidiabetic activity of medicinal plants depends upon variety of mechanisms. Generally, the 
mechanisms of action could be grouped as: pancreatic beta cell potassium channel blocking, 
adrenomimeticism, cAMP (secondary messenger) stimulation; providing certain necessary 
elements like calcium, zinc, magnesium, manganese and copper for the beta-cells; Inhibition of 
β-galactocidase and α-glucocidase; preventing oxidative stress that is possibly involved in 
pancreatic β-cell dysfunction found in diabetes (33); Stimulation of glycogenesis, glycolysis and 
citric acid cycle and hexose monophosphate shunt; inhibition of gluconeogenesis and 
glycogenolysis (34-36); improvement in digestion along with reduction in blood sugar and urea; 
protection of destruction and promotion of regeneration of the β‐cells, initiate insulin release; 
reduction in insulin resistance and/or inhibition in renal glucose reabsorption (37).  
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The development of metformine was based on the use of Galega officinalis to treat diabetes. 
Galega officinalis is rich in guanidine which is the hypoglycemic component. Because guanidine 
is too toxic for clinical use, the alkyl biguanides synthalin A and synthalin B were introduced as 
oral antidiabetic medications in Europe in the 1920s but were discontinued after insulin became 
more widely available. The experience with guanidine and biguanides was the base for the 
development of metformine (38).  
The World Health Organization (WHO) has encouraged and recommended the use of herbs as an 
alternative therapy for diabetes mellitus since medicinal plants are often less expensive, easily 
accessible, less toxic and suitable to use. Though a wide range of medicinal plants are in use 
world over, many of them are without valid scientific sanctity. Apparently, a systematic 
scientific scrutiny of the antidiabetic potentials of these plants has become a matter of utmost 
importance to justify their application in ethnomedicine (35, 39). Therefore, much effort should 
be focused on assessing natural products and herbal plants for the discovery of potentially useful 
alpha-glucosidase inhibitors and aldose reductase inhibitors or other treatment approaches to 
diabetes (32). 
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1.3 The experimental plant, Calpurnia aurea (Ait.) Benth. (Fabaceae) 
The flowering plant family Leguminosae (Fabaceae) contains approximately 650 genera and 
nearly 20,000 species distributed throughout the world in many ecological settings, from deserts 
of high latitudes to seasonally dry or wet tropical forests of equatorial regions (40, 41). 
The genus Calpurnia (Leguminosae) involves seven species which are widely distributed in 
Africa. Calpurnia aurea (Ait.) Benth. (Fabaceae) is a yellow-flowered, multi-stemmed, 3-4 m 
tall small tree or shrub widely distributed in Africa, ranging from the Cape Province to Eritrea, 
and it also occurs in southern India (42, 43). Two subspecies of Calpurnia aurea are recognized, 
namely subspecies (subsp.) aureu (occurs in Ethiopia, Zaire, Zimbabwe, Angola, West Africa, 
and Cape Province) and subsp. Indica which is confined in India (44). 
 
Figure 4: Picture of Calpurnia aurea (Ait.) Benth. (By Yaschilal Muche) 
Calpurnia aurea from Ethiopia is known locally as ―digitta‖ (Amharic) or ―cheka‖ (Oromiffa). 
The plant is used in traditional medicine of Ethiopia to treat diverse medical conditions. It is used 
to treat amoebiasis, giardiasis, malaria, diarrhoea, rabies, diabetes and hypertension (45, 46). The 
plant has also been used as an insecticide to kill lice (47), to induce uterine contractions (48), and 
to treat coughs, amoebic dysentery, syphilis, leishmaniasis, tapeworm, trachoma, ringworm, 
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scabies, elephantiasis, abscesses and wounds as well as stomach ache, vomiting, headache and 
eye diseases (49-52).  
Experimental studies have reported that Calpurnia aurea subspecies aurea has antimalarial, 
antihypertensive, antidiarheal, antibacterial, antioxidant and anticancer activities (42, 53-58). The 
plant has hepatoprotective effect against HAART induced hepatotoxicity, and it can attract and 
immobilize or kill ticks (43, 59).  
Preliminary Phytochemical screening of 80% methanol extract of Calpurnia aurea seeds showed 
the presence of alkaloids, tannins, flavonoids, terpenoids, saponins and phenols (55). The result 
of preliminary phytochemical screening of 80% methanol extract of Calpurnia aurea leafs 
showed the presence of several secondary metabolites including alkaloids, cardiac glycosides, 
flavonoids, phenols, phytosteriods, saponins, terpenoids, tannins, proanthocyanidins and 
flavonols (42, 53, 54).  
Different pharmacologically active phytochemicals has been isolated from C. aurea. Studies 
reported the isolation of agglutinins to antigens A and B of human erythrocytes, and the novel 
quinolizidine alkaloid, calpurnine from the seeds of Calpurnia aurea subsp. aurea. Subsequent 
investigations reported several more quinolizidine alkaloids which are characteristic 
chemotaxonomic markers for the family, Fabaceae (58, 60, 61). Apart from the quinolizidine 
alkaloids, the flavonoids vicenin-2 (6,8-di-β-D-glucopyranosyl-5,7,4'-trihydroxyflavone), butin 
(7,3',4'-trihydroxyflavanone) and 3'-hydroxydaidzein (7,3',4' trihydroxyisoflavone) were isolated 
from the seeds of C. aurea, showing flavonoids being the other major class of compounds 
consistently found in the Fabaceae (62). The stem and bark of Calpurnia aurea was investigated 
phytochemically and yielded a quinolizidine alkaloid, calpurnine which is also found in other 
parts of the plant. Isoflavones and a pterocarpan were also extracted from the stem and bark of 
calpurnia aurea. Isoflavones are also found in the seeds of Calpurnia aurea. Furthermore, the 
isoflavones isolated from the seeds of Calpurnia aurea were shown to have moderate activity 
against the renal, melanoma and breast cancer cell lines (58).  
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1.4 Justification of the study 
Therapies of DM developed along the principles of western medicine are often limited in 
efficacy, carry the risk of adverse effects, and are often too costly, especially for the developing 
world (28). Therefore, treating diabetes mellitus with plant derived compounds which are 
accessible and do not require laborious pharmaceutical synthesis seems highly attractive. 
Calpurnia aurea (Ait.) Benth. (Fabaceae) is traditionally used for the treatment of DM in 
Ethiopia. An ethnobotanical survey done in shenasha, Agew-awi and Amhara peoples of 
northwest Ethiopia reported that the leaf as well as the seed of the plant is used orally for the 
treatment of DM (45). Another survey done in nekemtae town (east wollega, Ethiopia) reported 
leaf decoction of the plant is taken orally to treat DM (46). However; the antidiabetic activity of 
this medicinal plant is not scientifically validated.  
There is considerable evidence that induction of oxidative stress is a key process in the 
pathogenesis of DM and diabetic complications (14, 63, 64). The protective effect of 
antioxidants has been explained in experimental and epidemiological studies, which have 
demonstrated that antioxidants might be helpful in treating diabetes and its complications 
through prevention of oxidative stress (13, 14, 64). Calpurnia aurea (Ait.) Benth. leaves and 
seeds have strong in-vitro antioxidant activities (42, 57). As a result, this medicinal plant may 
have antidiabetic activity. Additionally, the antidiabetic activity of medicinal plants is mainly 
due to the presence of alkaloids, phenolic compounds, flavonoids, terpenoids and other 
constituents (28, 30, 32, 65, 66). The hydromethanolic extract of both Calpurnia aurea seeds and 
leaves also contain these secondary metabolites known to have blood glucose lowering activity 
(53-55) so that the plant may have antidiabetic activity.  
Accordingly, it is justifiable to conduct a study aimed at the evaluation of the effect of the plant 
materials on DM and its complication, diabetic dyslipidemia using in vivo models. Besides, the 
finding of this study might serve as baseline information for scientific community to further 
investigate the plant Calpurnia aurea by initiating advanced studies on molecular mechanisms 
with identification of the specific agent responsible for the antidiabetic effect, which may serve 
as a lead compound for the development of new antidiabetic drugs.  
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2 Objectives  
2.1 General objective 
To evaluate the antidiabetic and antidyslipidemic activities of the hydromethanolic leaf and seed 
extracts of Calpurnia aurea (Ait.) Benth. (Fabaceae) in mice 
2.2 Specific objectives 
 To carry out acute oral toxicity test of the leaf and seed extracts of calpurnia aurea (Ait.) 
Benth.   
 To determine hypoglycemic effect of calpurnia aurea leaf and seed extracts in 
normoglycemic mice  
 To determine antihyperglycemic activity of the leaf and seed extracts in oral glucose 
loaded mice 
 To evaluate antihyperglycemic activity of the leaf and seed extracts on streptozotocin-
induced diabetic mice 
 To examine effect of the leaf and seed extracts of the plant on body weight of 
streptozotocin-induced diabetic mice 
 To determine the effect of the leaf and seed extracts on serum lipid level of 
streptozotocin-induced diabetic mice 
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3 Materials and Methods 
3.1 Materials  
3.1.1 Collection of plant materials 
Fresh leaves and matured seeds of Calpurnia aurea were collected from Anbessamie (located in 
south Gondar zone of Amhara region, northwest Ethiopia) in January, 2017. Taxonomic 
identification of the plant was done by a botanist (Mr. Abyu Eniyew), and a specimen of the 
plant material was preserved in the Herbarium of biology department, University of Gondar with 
a voucher number YM001 for future reference. 
3.1.2 Drugs, chemicals and instruments 
The following drugs, chemicals and instruments were used during the study. Streptozotocin 
(Sigma Aldrich, Germany), glibenclamide (Julphar pharmaceuticals, Ethiopia), Citric acid 
monohydrate (Lab tech chemicals, India), Tri-sodium citrate dihydrate (Blulux Labratories, 
India), Methanol absolute (Nice chemicals, India), 40% glucose solution (Reyoung 
pharmaceuticals, China), sterilized water for injections (Nirma Ltd., India), Analytical balance, 
pH meter, i-QARE DS-W
®
 blood glucose meter and strips (Alliance international, Taiwan), 
Distilled water, automated chemistry analyzer (Shenzhen Mindray Bio-medical Electronics Co., 
Ltd, China), Whatman filter paper No.1, beakers, funnels, measuring cylinder, glass rod, spatula, 
pipettes, gavage (oral feeding syringe), animal Cages, Insulin syringe with needle, oven, 
desiccators. All chemicals used were of analytical grade. 
3.2 Methods  
3.2.1 Preparation of plant crude extracts 
The leaves and seeds of the plant were thoroughly washed with distilled water to remove dirt and 
then dried under shade with optimal ventilation. Then, the dried leaves and seeds were 
pulverized separately. The coarse powdered plant materials (900 gram powdered leaves and 1 kg 
powdered seeds) were macerated in 80% methanol for 72 hours and then the extracts were 
filtered by using whatman filter paper No.1. The marc was re-macerated two times with fresh 
solvent, each for 72 hours and the filtrates obtained from the successive maceration were dried in 
an oven at 40 degree centigrade. Finally, the dried leaf and seed extracts were kept separately in 
a desiccator until used for the experiment. 
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3.3 Experimental animals 
Healthy Male Swiss albino mice (weighing 25-30 g and age of 8-12 weeks) were used in the 
study except for the acute oral toxicity tests. The mice were obtained from the Ethiopian public 
health institute (EPHI) and then they were kept in the animal house of pharmacology department, 
University of Gondar. The animals were maintained under standard conditions (12 h light and 12 
h dark cycle) and allowed free access to standard pellet laboratory diet and water ad libitum. 
Animals were acclimatized to the laboratory conditions for 1 week before the initiation of the 
experiment. 
3.4 Acute toxicity study 
Acute oral toxicity tests were done for the leaf and seed extracts of the plant. The tests were done 
based on the limit and main test recommendations of OECD No 425 Guideline (67). On the first 
day of the test, one female Swiss albino mouse fasted for 3 hours was given 2000 mg/kg of the 
extract orally. Then the mouse was kept under strict observation for physical or behavioral 
changes for 24 h, with special attention during the first 4 hours. Because mortality was not 
observed in the first mouse which received the leaf extract, other four female mice fasted for 3-4 
hours were sequentially administered a single dose of 2000 mg/kg of the leaf extract and then 
observed in the same manner. The observation was continued for a total of 14 days for any sign 
of toxicity and mortality. Unlike the leaf extract, mortality was observed in the first mouse that 
received 2000 mg/kg of the seed extract. Thus, the main test was conducted for the seed extract 
in order to determine the LD50. In the main test single female mice were dosed in sequence at 48 
hour intervals using a starting dose, 175mg/kg and a dose progression factor, 3.2. The dosing 
was stopped after testing 6 consecutive animals because 5 reversals (response, which is death of 
mouse, was observed at some dose, and a non-response is observed at the next dose tested) were 
occurred. Animals were observed individually at least once during the first 30 minutes after 
dosing, periodically during the first 24 hours with special attention given during the first 4 hours, 
and daily thereafter, for a total of 14 days. 
3.5 Grouping and dosing of animals 
Male animals were used in all animal models (normoglycemic mice, oral glucose loaded mice, 
single dose treated diabetic mice, and repeated dose treated diabetic mice) because female mice 
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are less sensitive to STZ (68, 69), and they are also less sensitive to insulin compared to male 
animals (70). In the normoglycemic, oral glucose loaded and single dose treated diabetic animal 
models, mice were randomly divided into eight groups (each group containing 6 mice). In all 
three animal models; Group I (negative control) was treated with 10ml/kg distilled water (DW); 
Group II, III and IV were treated with 100 mg/kg, 200 mg/kg and 400 mg/kg hydromethanolic 
leaf extract respectively; Group V, VI and VII were treated with 2.75 mg/kg, 5.5 mg/kg and 11 
mg/kg hydromethanolic seed extract respectively; whereas Group VIII (positive control) was 
treated with the standard drug, glibenclamide (5 mg/kg). In the repeated dose treated diabetic 
animal model, mice were randomly divided into nine groups (8 groups of diabetic mice and 1 
additional group of normal mice, each group containing 6 mice). Group I (diabetic control) was 
treated with 10 ml/kg DW; Group II, III and IV (diabetic test groups) were treated with 100 
mg/kg, 200 mg/kg and 400 mg/kg hydromethanolic leaf extract respectively; Group V, VI and 
VII (diabetic test groups) were treated with 2.75 mg/kg, 5.5 mg/kg and 11 mg/kg 
hydromethanolic seed extract respectively; Group VIII (diabetic positive control group) was 
treated with the standard drug, 5 mg/kg glibenclamide; whereas Group IX (normal control) was 
treated with 10 ml/kg DW. Age and body weight of animals were matched across groups in each 
animal model. 
The three doses of each plant extract were determined based on the results of acute oral toxicity 
studies. Glibenclamide (5 mg/kg) was selected as a standard drug for this study based on reports 
of earlier studies (71-73). The study was conducted using oral route of administration because 
people traditionally use the plant materials via the oral route (45, 46). All the doses were 
administered at a volume not greater than 10ml/kg body weight of mice (67).  
3.6 Measurement of blood glucose level 
In all cases, blood samples for blood glucose measurement were withdrawn from the tail vein of 
each animal by cutting the tip of the tail aseptically. BGL was measured using a DS-W
®
 blood 
glucose meter. Measurement of the blood glucose level was done in triplicate and the average 
value was taken.  
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3.7 Induction of experimental diabetes  
Diabetes was induced using streptozotocin. The drug was dissolved in 0.1 M cold citrate buffer 
(pH=4.5). The freshly prepared solution was then administered intraperitonially at 150 mg/kg 
dose to mice (74) which were fasted overnight for 16 hours prior to administration. Free access 
to food and water was allowed to the animals thirty minutes after administration of STZ. Six 
hours after the administration of STZ, animals were allowed to drink 5% glucose solution for the 
next 24 hours to prevent death secondary to hypoglycemic shock. Four days after STZ injection, 
animals were screened for diabetes. Mice which showed fasting blood glucose level > 200 mg/dl 
were included in the study as diabetic mice (72, 75). Immediately after screening, STZ-induced 
diabetic animals were assigned randomly into different groups to perform the experimental 
studies. The Bedding of the cages was changed every day after STZ injection to provide dry 
bedding for polyuric diabetic animals. 
In order to prepare 0.1 molar citrate buffer, Citric acid monohydrate (2.101g) and Trisodium 
citrate dihydrate (2.941g) were accurately weighted and then separately dissolved in 100 ml of 
sterilized water for injection to prepare 0.1 M citric acid and 0.1 M sodium citrate solutions. 
After preparation of the solutions, 50 ml of the citric acid solution was mixed with 50 ml sodium 
citrate solution and then pH was adjusted to 4.5 with 0.1 M sodium citrate solution (76).  
3.8 Assessing hypoglycemic activity in normoglycemic mice 
Mice, which were fasted overnight for 16 hours, were randomly divided into eight different 
groups (6 animals per group). Then, the animals were treated according to their respective 
grouping as mentioned above. Blood glucose level of each mouse was measured just before 
treatment (at 0 hr) as baseline, and then at 1, 2, 4 and 6 hours post-treatment. 
3.9 Evaluating effect of extracts on oral glucose tolerance test  
Mice were used for the oral glucose tolerance test as overnight fasting increases insulin 
sensitivity (insulin-stimulated glucose utilization) specifically in mice (77, 78); thus the model 
can be sensitive for screening anti-hyperglycemic activity of the plant extracts.  Overnight fasted 
(for 16 hours) mice were randomly divided into 8 groups (6 mice per group). Then, mice were 
treated with distilled water, hydromethanolic plant extracts and glibenglamide according to their 
respective grouping.  Thirty minutes following each administration (71, 79), 2.5 g/kg of glucose 
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solution was administered to each animal (71). Blood glucose levels were measured for each 
animal just before treatment (at 0 minute) as baseline, and then at 30, 60 and 120 minutes 
following glucose administration (71, 80). 
3.10 Assessing antihyperglycemic activity of single dose of the extracts in 
streptozotocin induced diabetic mice 
After overnight fasting for 16 hours, streptozotocin induced diabetic mice were assigned 
randomly into 8 groups (each group containing 6 diabetic mice). Then, mice were treated with 
distilled water, hydromethanolic plant extracts and glibenglamide according to their respective 
grouping. Blood glucose level was measured just before treatment (at 0 hr) as baseline, and then 
at 2, 4, 6 and 8 hours post-treatment. 
3.11 Assessing antihyperglycemic activity, effect on body weight and 
antidyslipidemic activity of repeated doses of the extracts in streptozotocin-
induced diabetic mice  
After overnight fasting for 16 hours, STZ-induced diabetic mice and normal mice were randomly 
assigned into 9 groups (8 groups of diabetic mice and 1 group of normal mice, each group 
containing 6 mice). Then, mice were treated with distilled water, plant extracts and 
glibenglamide once daily for 14 days according to their respective grouping as explained above. 
Blood glucose level and body weight of diabetic mice were measured just before starting 
treatment on the 1
st
 day of treatment (four days after STZ injection) as baseline, and then on the 
7
th
  and 14
th
 day of treatment following overnight fasting for 16 hours (81). 
On the 15
th
 day, blood samples were collected in a sterile tube through exsanguination of the 
overnight fasted (for 16 hours) diabetic mice under diethyl ether anesthesia. The blood samples 
were left at room temperature for 2 hours to allow coagulation, and then centrifuged at 2000 rpm 
for 10 minutes. The supernatant was immediately separated from the pellet to prepare serum 
samples in order to determine the level of triglyceride (TG), total cholesterol (TC), and high 
density lipoprotein cholesterol (HDL-C) using automated chemistry analyzer.  
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3.12 Ethical considerations  
The experiment was conducted in accordance with the Guide for the Care and Use of Laboratory 
Animals (82), and the proposal of the study was submitted and approved by the ethical review 
committee of  the school of pharmacy, university of Gondar before the commencement of the 
study. 
3.13 Statistical analysis  
The data were expressed as mean ± standard error of the mean. Means of all parameters among 
groups and within a group were compared using one way ANOVA followed by Tuckey’s post 
hoc test. P-values < 0.05 were considered statistically significant. SPSS Version 20 Software was 
used for statistical analysis. Percent reduction of blood glucose level was calculated using the 
formula: [(G0 – Gp) ̸ G0]100, where G0 is baseline blood glucose level; and Gp is post treatment 
blood glucose level. 
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4 Result  
4.1 Percentage yield of plant material extraction 
At the end of the extraction process, 154 grams of dried dark-brown gummy leaf extract and 136 
grams of dried yellowish brown gummy seed extract were harvested. The percentage yield of the 
hydromethanolic leaf extract was 17.11 % (w/w); whereas the percentage yield of the seed 
extract was found to be 13.60 % (w/w).  
4.2 Acute oral toxicity study 
The Acute toxicity study of Calpurnia aurea leaf extract (CALE) didn’t show mortality in the 
animals at the limit dose of 2000 mg/kg during the observation time. Thus, the median lethal 
dose (LD50) of the leaf extract is greater than 2000 mg/kg. Besides, the toxicity study of CALE 
did not reveal any signs of toxicity; behavioral, neurological, autonomic or physical changes 
such as alertness, motor activity, restlessness, convulsions, coma, diarrhea and lacrimation.  
Acute oral toxicity study of Calpurnia aurea seed extract (CASE) revealed that the seed of the 
plant is toxic compared to the leaf. It was found that the LD50 of CASE is between 55 mg/kg 
and 175 mg/kg based on the main test recommendations of OECD guideline no 425 (Table 1). 
Table 1: Acute oral toxicity study of the 80 % methanolic seed extract of Calpurnia aurea 
Test 
sequence 
Mouse ID Dose (mg/kg) Outcome  Remark  
1 1 175 Dead  Convulsion was followed by death within 10 
minutes after dosing 
2 2 55 Survived  No death and sign of toxicity was observed 
3 3 175 Dead  Convulsion was followed by death within 10 
minutes after dosing 
4 4 55 Survived  No death and sign of toxicity was observed 
5 5 175 Dead Convulsion was followed by death within 10 
minutes after dosing 
6 6 55 Survived  No death and sign of toxicity was observed 
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4.3 Hypoglycemic activity of 80% methanolic leaf and seed extracts of Calpurnia 
aurea in normoglycemic mice 
The effect of hydromethanolic leaf and seed extracts of Calpurnia aurea on fasting blood 
glucose level of normal mice is summarized in Table 2. Between groups analysis revealed that 
no significant difference in baseline fasting BGL across groups. CASE 11 mg/kg significantly 
reduced the BGL at the 4
th
 and 6
th
 hours (p<0.05) compared to the negative control. But all the 
three groups treated with different doses of CALE didn’t show a significant reduction in BGL at 
all time points compared to the negative control group. It was found that BGL was significantly 
reduced by 5 mg/kg glibenclamide at the 2
nd
 (p<0.05), 4
th
 (p<0.01) and 6
th
 (p<0.05) hour 
compared to the negative control. Similarly, Comparing GLC treated group with extract treated 
groups, it was revealed that GLC (5mg/kg) significantly reduced the BGL at the 2
nd 
and 4
th
 hour 
(p<0.05) compared to 100 mg/kg CALE treated group; at the 2
nd
 hr (p<0.05) compared to 200 
mg/kg CALE treated group; at the 2
nd 
(p<0.01), 4
th
 (p<0.05) and 6
th
 (p<0.05) hour compared to 
the 400 mg/kg CALE treated group. There was no statistically significant difference in BGL 
when groups treated with different doses of leaf extract compared with each other at all time 
points. Similarly, different doses of CASE didn’t show statistically significant difference in BGL 
at all time points when compared with each other. When comparing the CALE treated groups 
with CASE treated groups, it was found that 11 mg/kg CASE significantly reduced the BGL 
(p<0.01) at the 6
th
 hour compared to 400 mg/kg CALE.  
Within group analysis showed that treatment with all the three doses of leaf extract and distilled 
water didn’t significantly reduce the BGL at all time points compared to the respective baseline 
BGL. It was found that 5.5 mg/kg CASE significantly reduced the BGL at the 6
th
 hr (p<0.05) 
compared to the baseline level with percentage reduction of 20.39%. Similarly, significant 
reduction in BGL was induced with 11 mg/kg CASE at the 4
th
 (p<0.01) and 6
th 
(p<0.001) hour 
compared to the baseline level with percentage reduction in BGL, 32.72% and 46.11% 
respectively. In addition, the standard dug (glibenclamide) reduced the BGL significantly at the 
2
nd
 (p<0.05), 4
th 
(p<0.001) and 6
th 
(p<0.001) hours compared to the baseline level with 
percentage reduction of 32.37%, 40.63% and 46.61% respectively. 
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Table 2: Hypoglycemic activity of Hydromethanolic Calpurnia aurea leaf and seed extracts in 
normoglycemic mice 
Group Blood glucose level (mg/dl) 
0 hr 1 hr 2 hr 4 hr 6 hr 
DW 10ml/kg 68.17±7.97 70.22±7.90 72.33±8.09 73.5±7.33 68.06±7.99 
CALE 100mg/kg 70.67±4.36 73.78±2.76 72.61±3.42 66.33±2.08 64.00±3.88 
CALE 200mg/kg 68.83±4.14 73.83±4.08 71.56±4.59 65.56±2.56 56.33±4.92 
CALE 400mg/kg 76.72±3.21 79.11±5.96 83.17±3.89 67.17±5.29 67.39±6.61 
CASE 2.75mg/kg 69.00±2.52 72.17±9.64 62.56±8.34 60.56±10.17 58.11±10.47 
CASE 5.5mg/kg 74.61±3.81 74.00±3.13 72.28±2.41 61.89±1.90 59.39±5.14β1 
CASE 11mg/kg 70.11±3.71 62.50±4.40 59.39±2.73 47.17±3.59a1 β2 37.78±3.80a1 d1 β3 
GLC 5mg/kg 70.56±5.86 54.00±5.34 47.72±5.03a1 b1 c1 d2 f1 β1 41.89±2.73a2 b1 d1 β3 37.67±2.4a1 d1 β3 
Each value represents mean ± S.E.M, n=6 for each treatment. a compared to the negative control, b compared to CALE 100mg/kg, 
c compared to CALE 200mg/kg, d compared to CALE 400mg/kg, f compared to CASE 5.5 mg/kg, β compared to baseline blood 
glucose level. 1p < 0.05, 2p < 0.01 and 3p < 0.001. CALE = calpurnia aurea leaf extract, CASE = calpurnia aurea seed extract, 
DW = distilled water, GLC = glibenclamide. 
4.4 Antihyperglycemic activity of the hydromethanolic leaf and seed extracts of 
Calpurnia aurea in oral glucose loaded mice 
There was no significant difference in baseline BGL across groups just before the administration 
of DW, extracts and glibenclamide (Table 3). Between groups analysis showed that 5.5 mg/kg 
and 11 mg/kg CASE significantly reduced the hyperglycemia (p<0.05 in both cases) at the 2
nd
 
hour compared to the negative control. But, it was found that all doses of CALE didn’t show a 
significant reduction in hyperglycemia at all time points compared to the negative control. 
Similarly, 5 mg/kg GLC reduced the hyperglycemia significantly at the 1
st
 (p<0.05) and 2
nd 
(p<0.001) hour post glucose administration compared to the vehicle treated group. Comparing 
the GLC treated group with plant extract treated groups; 5 mg/kg GLC significantly reduced the 
hyperglycemia at the 2
nd
 hour (p<0.05) compared to 200 mg/kg CALE. There was no statistically 
significant difference in BGL at all time points when all the six plant extract treated groups 
compared with each other. 
Within a group analysis showed that oral glucose loading caused a statistically significant 
(p<0.001) increment in BGL at 30 minute in all groups compared to the baseline fasting BGL 
regardless of the treatments given. Additionally, significant hyperglycemia was observed at 1 hr 
23 
 
 
post glucose load in all groups, except GLC (5 mg/kg) treated group, compared to the respective 
baseline BGL. But there was no statistically significant difference in BGL at the 2
nd
 hour 
compared to the baseline level in all groups. Besides, significant reduction in BGL was observed 
at 60 and 120 minute in all groups including the negative control compared to the respective 
BGL at 30 minute post glucose load. 
Table 3: Effect of Calpurnia aurea leaf and seed extracts on oral glucose tolerance in normal 
mice 
Group  Blood glucose level (mg/dl) 
0 min 30 min  60 min 120 min 
DW 10 ml/kg 87.06±8.25 202.95±15.84β3 142.17±15.66β1 µ1 112.45±13.29µ3 
CALE 100 mg/kg 85.83±8.55 199.50±15.22β3 138.06±16.56β1 µ1 84.33±6.94µ3 
CALE 200 mg/kg 86.17±5.87 213.00±7.51β3 137.00±9.01β2 µ3 93.50±5.98µ3 
CALE 400 mg/kg 77.61±7.23 211.72±20.84β3 137.61±14.28β1 µ2 81.94±4.18µ3 
CASE 2.75 mg/kg 88.67±4.30 210.83±9.65β3 132.61±12.07β2 µ3 84.28±3.30µ3 
CASE 5.5 mg/kg 84.11±7.65 172.83±13.61β3 128.44±11.39β2 µ1 80.94±2.40a1 µ3 
CASE 11 mg/kg 76.50±2.69 202.56±17.12β3 130.22±11.38β2 µ3 76.45±2.96a1 µ3 
GLC 5 mg/kg 81.44±1.24 180.72±8.75β3 82.83±5.43a1 µ3 61.78±8.59a3 c1 µ3 
Each value represents mean ± S.E.M, n=6 for each treatment. a compared to the negative control, c compared to CALE 200mg/kg, 
β compared to baseline blood glucose level, µ compared to the blood glucose level at 30 minute. 1p < 0.05, 2p < 0.01 and 3p < 
0.001. CALE = calpurnia aurea leaf extract, CASE = calpurnia aurea seed extract, DW = distilled water, GLC = glibenclamide. 
Time refers to time after oral glucose administration. 
4.5 Antihyperglycemic activity of single dose of the leaf and seed extracts of 
Calpurnia aurea in streptozotocin-induced diabetic mice 
A total of 69 male Swiss albino mice were injected with Streptozotocine and 52 of them were 
found to be diabetic (fasting BGL > 200 mg/dl) four days after STZ injection, with a success rate 
of 75.36%. Among the 52 diabetic mice, one died before the administration of the test substances 
and all the remaining animals survived until the end of the experiment.  
Antihyperglycemic activity of single dose of the extracts was studied in STZ induced diabetic 
mice. As shown in Table 4, between and within group analysis were performed to see BGL 
differences across the various groups and time points respectively. The between group analysis 
indicated that no significant difference in baseline fasting BGL across all groups. Similarly, there 
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was no significant difference in BGL across all groups at the 2
nd
 hour post treatment. Compared 
to the negative control, a significant BGL reduction was observed at 6
th
 and 8
th
 hour in 5.5 mg/kg 
and 11 mg/kg CASE treated groups; at 4
th
, 6
th
 and 8
th
 hour in 5 mg/kg GLC treated group. There 
was no statistically significant difference in BGL at all time points when groups treated with 
plant extracts compared to each other, and compared to the positive control. 
Within group comparison indicated that significant BGL reduction was not observed in CALE 
100mg/kg, CALE 200 mg/kg, CALE 400 mg/kg, CASE 2.75 mg/kg, CASE 5.5 mg/kg and DW 
treated groups at all time points compared to the baseline fasting BGL. However, percent 
reduction in BGL was recorded as; 32.58% in CALE 100 mg/kg treated group, 21.59% in CALE 
200 mg/kg treated group, 22.75% in CALE 400 mg/kg treated group, 27.47% in CASE 2.75 
mg/kg treated group and 50.15% in CASE 5.5 mg/kg treated group at 8
th
  hour compared to the 
respective baseline fasting BGL. CASE 11 mg/kg was able to decrease the BGL significantly at 
the 6
th
 and 8
th
 (p<0.05) hour compared to the initial value with percentage reduction of 46.36% 
and 51.47%, respectively. The standard drug, glibenclamide also produced a significant BGL 
reduction at the 4
th
, 6
th
 and 8
th
 (p<0.001) hour compared to the initial level. 
Table 4: Antihyperglycemic activity of single dose leaf and seed extracts of calpurnia aurea in 
STZ-induced diabetic mice 
Group  Blood glucose level (mg/dl) 
0 hr 2 hr 4 hr 6 hr 8 hr 
DW 10 ml/kg 394.11±31.03 383.06±27.65 396.39±26.71 397.45±18.52 399.61±22.00 
CALE 100 mg/kg 377.72±43.57 364.39±35.29 288.83±51.29 261.33±54.28 254.67±48.16 
CALE 200 mg/kg 314.39±31.99 291.11±38.52 254.78±56.26 250.06±51.84 246.50±56.51 
CALE 400 mg/kg 342.67±58.07 313.39±73.93 266.39±53.99 290.00±57.78 264.72±56.88 
CASE 2.75 mg/kg 369.45±33.27 307.00±62.98 255.00±49.74 245.50±57.01 235.11±49.68 
CASE 5.5 mg/kg 395.39±53.55 308.78±61.45 232.06±60.77 193.83±45.04 a1 197.11±54.32a1 
CASE 11 mg/kg 341.89±50.75 267.06±45.23 194.78±30.46 183.39±27.12a1 β1 157.83±19.81a2 β1 
GLC 5 mg/kg 368.50±43.02 283.39±39.09 176.61±14.01a1 β3 171.72±18.27a1 β3 155.72±13.59a2 β3 
Each value represents mean ± S.E.M, n=6 for each treatment. a compared to the negative control, β compared to baseline blood 
glucose level. 1 p < 0.05, 2 p < 0.01, 3 p < 0.001. CALE = calpurnia aurea leaf extract, CASE = calpurnia aurea seed extract, DW 
= distilled water, GLC = glibenclamide. 
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4.6 Antihyperglycemic activity, effect on body weight and antidyslipidemic activity 
of the repeated doses of extracts in streptozotocin induced diabetic mice 
4.6.1 Antihyperglycemic activity of the repeated doses of leaf and seed extracts of 
Calpurnia aurea in diabetic mice 
Between group analysis indicated that no significant difference in baseline fasting BGL across 
all groups of diabetic mice, but the baseline BGL of the diabetic groups was significantly higher 
than the baseline BGL of the normal control (Table 5). Groups treated with 2.75 mg/kg, 5.5 
mg/kg and 11 mg/kg CASE and 5 mg/kg GLC showed significant reduction in blood glucose 
level on the 7
th
 and 14
th
 day of treatment compared to the diabetic control. There was no 
statistically significant difference in BGL at all time points when groups treated with plant 
extracts compared with each other. Similarly, GLC treated group showed no significant 
difference in BGL at all time points when compared to plant extract treated groups.  
Within group analysis revealed that all the three doses of CASE and the standard drug reduced 
the BGL significantly at the 7
th
 and 14
th
 day of treatment compared to the baseline level. But 
groups treated with different doses of CALE, the diabetic control and the normal control didn’t 
show a significant change in BGL at all time points compared to the baseline level. 
Table 5: Antihypeglycemic activity of repeated doses of Calpurnia aurea leaf and seed extracts 
in STZ-induced diabetic mice 
Group  Fasting blood glucose level (mg/dl) Percent reduction 
in baseline BGL 
Baseline 7
th
 day 14
th
 day 7
th
 day 14
th
 day 
Diabetic control 394.11±31.0
n3
 383.67±45.83
n3
 387.00±47.77
n3
 2.6% 1.8% 
CALE 100 mg/kg 377.72±43.57n3 251.39±42.39n2 250.44±42.30n1 33.45% 33.69% 
CALE 200 mg/kg 314.39±31.99n2 243.56±36.29n1 239.94±35.8n1 22.53% 23.68% 
CALE 400 mg/kg 342.67±58.07n3 252.72±29.92n2 250.61±29.57n1 26.25% 26.87% 
CASE 2.75 mg/kg 369.45±33.27n3 222.17±34.81a1 β1 218.95±34.59a1 β1 39.86% 40.73% 
CASE 5.5 mg/kg 395.39±53.55n3 195.83±24.23a2 β2 191.17±23.91a2 β2 50.47% 51.65% 
CASE 11 mg/kg 341.89±50.75n3 154.39±23.19a3 β2 148.22±23.22a3 β2 54.84% 56.65% 
GLC 5 mg/kg 368.50±43.02n3 145.56±26.72a3 β3 136.67±26.41a3 β3 60.49% 62.91% 
Normal control 76.83±2.51 77.67±2.50 78.67±2.75 -1.09% -2.4% 
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Each value represents mean ± S.E.M, n=6 for each group. a compared to the diabetic control, n compared to the normal control. β 
compared to baseline blood glucose level. 1 p < 0.05, 2 p < 0.01 and 3 p < 0.001. CALE = calpurnia aurea leaf extract, CASE = 
calpurnia aurea seed extract, GLC = glibenclamide. 
 
Figure 5: Effect of repeated doses of Calpurnia aurea leaf and seed extracts on blood glucose 
level of diabetic mice. CALE = calpurnia aurea leaf extract, CASE = calpurnia aurea seed 
extract, GLC = glibenclamide, BGL = blood glucose level 
4.6.2 Effect of the repeated doses of leaf and seed extracts of Calpurnia aurea on body 
weight of diabetic mice 
There was no significant difference in body weight of mice across all groups including the 
normal control just before induction of DM with STZ. STZ produced significant loss of body 
weight in the diabetic control at the 7
th
 and 14
th
 day of treatment compared to the normal control. 
The results shown in Table 6 revealed that all the three doses of CASE (2.75, 5.5 and 11 mg/kg) 
and 5 mg/kg glibenclamide showed significant improvement in body weight at the 14
th
 day of 
treatment compared to the diabetic control. There was no statistically significant difference in 
body weight at all time points when groups treated with the plant extracts compared with each 
other.  
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Intra-group analysis was done to compare the baseline body weight, which was measured just 
before starting treatment (four days after STZ administration), with body weight at the 7
th
 and 
14
th
 day of treatment. Accordingly, it was found that groups treated with the three doses of 
CALE (p<0.05) and the diabetic control (p<0.01) showed significant body weight reduction at 
the 14
th
 day of treatment compared to the respective baseline body weight. 
Table 6: Effect of repeated doses of the leaf and seed extracts of Calpurnia aurea on body weight 
of STZ-induced diabetic mice 
Group  Body weight (g) 
Before induction of 
Diabetes 
Baseline  7
th
 day of 
treatment 
14
th
  day of 
treatment 
Diabetic control 28.67±0.95 26.77±0.89 23.88±1.24n2 20.88±1.15n3 β2  
CALE 100 mg/kg 28.83±1.09 27.98±0.95 25.07±1.06 n1 23.78±0.86n3 β1  
CALE 200 mg/kg 28.83 ±0.91 26.82±1.18 24.83±0.98 n1 22.97±0.76n3 β1 
CALE 400 mg/kg 28.75±0.96 27.70±0.99 25.00±1.02 n1 23.25±1.16n3 β1 
CASE 2.75 mg/kg 28.58±0.99 27.92±1.40 26.93±1.72 27.00±1.75a2 
CASE 5.5 mg/kg 28.50±0.75 27.50±0.82 26.68±0.90 26.95±0.89a2 
CASE 11 mg/kg 28.92±0.72 27.58±1.01 27.18±1.01 27.67±0.98a3 
GLC 5 mg/kg 28.75±0.48 26.07±0.73 25.95±0.71 26.53±0.72a2 
Normal control 29.00±0.47 29.45±0.36 30.03±0.53 30.70±0.59 
Each value represents mean ± S.E.M, n=6 for each group. a compared to the diabetic control, n compared to the normal control. β 
compared to baseline body weight. 1 p < 0.05, 2 p < 0.01 and 3 p < 0.001. CALE = calpurnia aurea leaf extract, CASE = calpurnia 
aurea seed extract, GLC = glibenclamide. 
4.6.3 Effect of the repeated doses of leaf and seed extracts of Calpurnia aurea on serum 
lipid level of diabetic mice 
There was a significant elevation (p<0.001) of serum total cholesterol, triglycerides, and 
significant reduction (p<0.001) of HDL cholesterol in the diabetic control mice compared to the 
normal mice (Table 7). The administration of 5.5 mg/kg and 11 mg/kg Calpurnia aurea seed 
extract for 14 days significantly reduced (p<0.05) the levels of serum total cholesterol while 
significantly increasing (p<0.05) the HDL cholesterol level. Similarly, all the three doses of 
CASE significantly reduced the level of serum triglyceride. The standard drug glibenclamide 
also significantly reduced (p<0.001) the serum cholesterol and triglyceride level while increasing 
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(p<0.01) the HDL cholesterol. There was no significant difference in the level of serum TC, TG 
and HDL-C when groups treated with plant extracts compared with each other.  
Table 7: Effect of repeated doses of Calpurnia aurea leaf and seed extracts on serum lipid level 
of diabetic mice 
Groups Serum lipid level (mg/dl) 
TC TG HDL-C 
Diabetic control  191.33±4.07n3 164.83±13.49n3 22.17±3.05 n3 
CALE 100mg/kg 168.83±3.67n3 154.00±6.71n3 28.17±2.10 
CALE 200 mg/kg 171.67±15.40n3 154.67±6.28n3 29.83±3.91 
CALE 400 mg/kg 168.87±11.17n3 148.33±4.68n3 30.50±1.34 
CASE 2.75 mg/kg 157.67±10.60n3 128.50±6.21a1 n3 33.00±2.88  
CASE 5.5 mg/kg 150.33±10.60a1 n3 127.50±6.73a1 n3 36.50±2.64a1 
CASE 11 mg/kg 149.67±4.06a1 n3 119.50±4.22a2n2 37.00±0.58a1 
GLC 5 mg/kg 99.50±8.27a3 b3 c3 d3 e3 f2 g2 77.50±5.55a3 b3 c3 d3 e3 f3 g2 38.50±2.68a2 
Normal control 83.83±5.36 73.50±7.26 41.17±4.88 
Each value represents mean ± S.E.M, n=6 for each group. a compared to the diabetic control, b compared to CALE 100mg/kg, c 
compared to CALE 200mg/kg, d compared to CALE 400mg/kg, e compared to CASE 2.75mg/kg, f compared to CASE 5.5mg/kg, 
g compared to CASE 11mg/kg, n compared to the normal control. 1 p < 0.05, 2 p < 0.01 and 3 p < 0.001. CALE = calpurnia aurea 
leaf extract, CASE = calpurnia aurea seed extract, GLC = glibenclamide, TC = Total cholesterol, TG = Triglyceride, HDL-C = 
High density lipoprotein cholesterol. 
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5 Discussion 
Diabetes is one of the largest global health emergencies of the 21
st
 century (5). There is a need 
for safer and more effective treatment because currently available drug regimens for DM have 
definite disadvantages. Effective novel compounds with pan-target antidiabetic activity and 
proven long-term safety should be targeted for patients with coexisting lipid and glucose 
metabolic disorders. Thus investigating plant derived compounds, which are easily accessible 
and do not require laborious pharmaceutical synthesis, for the treatment of DM is an important 
research area (28, 81).  
There is no previous study on the acute oral toxicity profile of the 80% methanolic seed extract 
of Calpurnia aurea. But previous acute toxicity tests were done for the leaf extract, although 
there is discrepancy among the results of the studies (53, 54, 56). This study revealed that unlike 
the leaf extract which was safe at the dose of 2000 mg/kg, the hydroalcoholic seed extract of 
Calpurnia aurea was found to be relatively toxic with LD50 between 55mg/kg and 175mg/kg. 
This difference in toxicity might be due to qualitative and quantitative differences in the 
phytochemical content of the leaf and seed. 
In the present study, experimental diabetes in mice was induced using streptozotocin [2-deoxy-2-
(3-methyl-3-nitrosourea)-1-D-glucopyranose]. Streptozotocin induced diabetes is a known and 
well documented model of experimental diabetes in mice (83). Previous studies showed that 
single interaperitoneal injection of 150 mg/kg STZ can produce sustained hyperglycemia in mice 
at least for 8 weeks (84). Similarly, the present study revealed that STZ induced persistent 
hyperglycemia without significant change in BGL during the study period of two weeks as 
observed in the diabetic control mice.  STZ is a better diabetogenic agent than alloxan with wider 
species effectiveness and greater reproducibility, and this could be attributed to the fact that STZ 
is more stable in solution before and after injection in animals than alloxan (85). The 3 major 
mechanisms associated with pancreatic β cell death secondary to STZ exposure are DNA 
methylation, Nitric oxide and reactive Oxygen species Production (85). STZ toxicity to β cells is 
short-lived and further impairment of the surviving β cell function is due to hyperglycemic 
toxicity (86).  
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In this study, there were no detectable differences in baseline BGL across groups in each animal 
model; additionally the vehicle treated groups didn’t show significant reduction of BGL 
compared to the baseline level. However, significant reductions in BGL was observed in all 
models after the administration of the hydroalcoholic seed extract and standard drug, indicating 
changes induced on blood glucose level were attributed to treatments received.  
The study on normoglycemic mice revealed that the 80% methanolic seed extract of calpurnia 
aurea at the dose of 5.5 mg/kg and 11 mg/kg showed significant hypoglycemic activity. 
Similarly, the seed extract at the dose of 5.5 mg/kg and 11 mg/kg showed significant 
antihyperglycemic activity after administration of single dose of the extract in oral glucose 
loaded mice as well as in STZ induced diabetic mice. Additionally, all the three doses of CASE 
showed significant antihyperglycemic activity and improvement in body weight after 
administration of repeated doses of the extract in diabetic mice. The hypoglycemic and 
antihyperglycemic activities of the seed extract were dose dependant. In all cases, higher 
reduction in BGL was observed with 11mg/kg CASE. The seed extract showed a relatively 
delayed onset of blood glucose lowering action than the standard drug. This might be due to the 
presence of compounds with higher glycemic index that could give rise to free glucose after 
digestion and tend to raise BGL following absorption. The presence of such an effect in the face 
of the hypoglycemic actions by the active compounds could lead to a delay in the action of the 
plant extract (72). Unlike the seed extract, the leaf extract of calpurnia aurea didn’t show a 
statistically significant blood glucose lowering activity in all animal models, and it didn’t 
significantly improve the body weight of diabetic mice after 14 days of treatment. This suggests 
the seeds of the plant contain higher amount of the active phytochemicals than the leaves. 
The antidiabetic activity of medicinal plants is due to the presence of phytochemicals like 
alkaloids, phenolic compounds, flavonoids and terpenoids (28, 30, 32, 65, 66). Flavonoids are 
known to have insulinogenic and pancreatic beta cell regenerating activities (30, 32). Thus, blood 
glucose lowering effects of the hydroalcoholic extract of Calpurnia aurea seeds might be due to 
the presence of these different secondary metabolites with possible synergistic effects.  
It was interesting that antihyperglycemic activity in diabetic mice was observed with 
glibenclamide which produce its effect via selective blockage of ATP sensitive K
+
 channels 
31 
 
 
(KATP) in the plasma membrane of β-cells of the pancreas thereby it leads to cytosolic 
depolarization and release of endogenous insulin (87). This suggests single dose intraperitoneal 
administration of STZ at a dose of 150 mg/Kg didn’t cause complete destruction of β-cells; or 
few cells remained with the capacity to regenerate and secret insulin. 
The blood glucose lowering activity of the hydromethanolic extract of Calpurnia aurea seeds 
may be due to Potentiation of insulin effect either by increasing the secretion of insulin from beta 
cells of pancreas or by increasing the peripheral glucose uptake (88). However, detailed 
pharmacological and biochemical researches are required to identify the exact mechanism for the 
hypoglycemic and antihyperglycemic effects observed in the study. 
STZ-induced diabetes is characterized by severe loss in body weight (68, 73). Mice with severe 
hyperglycemia tend to lose a large percentage of their weight after STZ treatment (68, 84). 
Similarly, the present study revealed that STZ caused significant body weight loss in the diabetic 
control mice. The induction of diabetes with STZ leads to loss of body weight due to increased 
wasting of fat stores (89), muscle and tissue proteins (90, 91). Hence, the weight gain after 
repeated administration of the hydromethanolic Calpurnia aurea seed extract in STZ-induced 
diabetic mice suggests the antihyperglycemic activity of the extract.  
Lipid abnormality is one of the complications of diabetes mellitus, manifested mainly by high 
serum TG, TC and low HDL-C (21, 73). This lipid abnormality is due to activation of hormone 
sensitive lipase that leads to increased lipolysis and increased secretion of VLDL from the liver 
(20, 21). In addition, insulin deficiency causes decreased activity of lipoprotein lipase which 
leads to decreased clearance of VLDL and chylomicrons (22). In this study, STZ-induced 
diabetic control mice showed significantly increased serum TG, TC and decreased HDL-
cholesterol as expected. Administration of CASE for 2 weeks significantly reduced serum TG, 
TC, and increased HDL-C in a dose dependant manner, but all the three doses of the leaf extract 
didn’t show significant improvement in diabetic dyslipidemia. It is not known whether CASE 
had a direct effect on lipid metabolism or the antidyslipidemic activity is achieved only due to 
the controlled hyperglycemia. But, it can be concluded that CASE improves diabetic 
dyslipidemia. 
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6 Conclusion and Recommendation  
6.1 Conclusion  
In conclusion, this study revealed that the hydromethanolic extract of Calpurnia aurea seeds has 
significant antidiabetic activities justifying the traditional use of the plant for DM. The seed 
extract also showed improvement in diabetic dyslipidemia and body weight loss. But, the 
hydromethanolic extract of Calpurnia aurea leaves didn’t show significant antidiabetic and 
antidyslipidemic activity, and it didn’t improve body weight loss in diabetic animals. 
6.2 Recommendation  
In future studies, it is important to undergo fractionation and purification to isolate and identify 
the exact molecules which are responsible for the antidiabetic effect of the plant.  
Additionally, sub-acute and chronic toxicity tests should be done to further explain safety issues 
related to the traditional use of the plant. 
The medicinal values of Calpurnia aurea should be given further attention with priority to its 
antidiabetic activities.  
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8 Annex 
Pictures taken during the Experiment: 
   
  
 
 
  
